Exubrion Therapeutics® News

APRIL 13, 2023
Dog’s Best Friend? A New Pain Management Treatment For Osteoarthritis Is A Hit With Dog Owners
Read Article on Forbes.com

APRIL 3, 2023
Multimodal Approach to Pain Management in Veterinary Rehabilitation
Read Article

JULY 22, 2022
Nonprofit gives free veterinary care to retired police dogs
Watch News Clip

MAY 26, 2022
New radioactive injection treats arthritis in dogs
Read Article

JANUARY 24, 2022
San Antonio Zoo treats first exotic animal with Synovetin OA
Read Article

JANUARY 7, 2022
SA Zoo treats Komodo dragon’s arthritis with new procedure developed for dogs
Read Article

NOVEMBER 22, 2021
Research shows lame dogs with joint deterioration are referred late, reducing successful treatment
Download Press Release

JULY 19, 2021
Treatment response in dogs to 117m Sn (tin) colloid
View Article

JANUARY 15, 2021
NRC guidelines pave the way for use of Synovetin OA® in dogs
Download Press Release

The Use of 117m Sn (tin) Colloid (Synovetin OA®) for Treatment of Naturally Occurring Grade 3 Elbow Osteoarthritis in Client Dogs
Download The Study

Appendices (available upon request):

A. Study Site Protocol
B. Canine Brief Pain Inventory (cBPI)
C. Statistical Report: cBPI and Lameness
D. Individual Dog Reports (15)
E. External Doses from Dogs Treated with 117mSN Report
F. Imaging Statistical Report and CT & MR Methodology

Synovetin OA® delivers sustained OA pain relief.1

Synovetin OA® provides targeted, non-systemic therapy.2


  • Data on file, Exubrion Therapeutics®.
  • Fox SM, Donecker JM. Donecker JM, Fox SM. Safety and effectiveness of Synovetin OA®: Results of three randomized trials evaluating treatment of naturally occurring canine elbow osteoarthritis. Exubrion Therapeutics®, July 2019.